Treatment of patients with Graves' ophthalmopathy by immunosuppressive agent and 99Tc-MDP.
- Author:
Weimin PAN
1
;
Tianzhi TAN
;
Quanlin WANG
;
Jianguo ZHENG
Author Information
1. Department of Nuclear Medicine, West China Hospital of Shichuan University, Chengdu 610041. pwmzj@sina.com
- Publication Type:Journal Article
- MeSH:
Graves Ophthalmopathy;
drug therapy;
Humans;
Immunosuppressive Agents;
therapeutic use;
Technetium Tc 99m Medronate;
therapeutic use
- From:
Journal of Biomedical Engineering
2002;19(2):300-323
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of this study was to evaluate the efficacy of immunosuppressive agents, 99Tc-MDP and both of them in treating patients with Graves' ophthalmopathy(GO). The efficacy was evaluated by randomized controlled trial involving a total of 66 patients. In 22 patients treated with immunosuppressive agents, the general efficacy rate was 19/22, the incidence rate of serious side-effect was 8/22. In 20 patients treated with 99Tc-MDP, the general efficacy rate was 17/20, the incidence rate of serious side-effect was 2/20. In 24 patients treated with immunosuppressive agents and 99Tc-MDP, the general efficacy rate was 22/24, the incidence rate of serious side-effect was 2/24. The results suggested that in the treatment of Graves' ophthalmopathy, when satisfactory efficacy was obtained, the serious side-effect and 'rebound' of symptom could be avoided by using immunosuppressive agents in combination with 99Tc-MDP.
